Onconova Therapeutics Stock News

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Avi Oler - Senior Vice President-Corporate Development and General Counsel Stev

NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patient

Onconova Therapeutics' (ONTX) CEO Steve Fruchtman on Q4 2021 Results - Earnings Call Transcript

Onconova Therapeutics (NASDAQ:ONTX) is scheduled to announce FY earnings results on Thursday, March 17th, after market close.The consensus EPS Estimate is -$0.92 and the consensus…

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022

Onconova Therapeutics Inc (ONTX) shares closed today at 5.2% above its 52 week low of $2.11, giving the company a market cap of $47M. The stock is currently down 12.9% year-to-date, down 79.3% over the past 12 months, and down 99.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 51.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 2.3% lower than its 5-day moving average, 12.1% lower than its 20-day moving average, and 34.5% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 43.2% The company's stock price performance over the past 12 months lags the peer average by 74.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Onconova Therapeutics Inc (ONTX) shares closed today at 0.5% above its 52 week low of $2.22, giving the company a market cap of $48M. The stock is currently down 11.8% year-to-date, down 78.4% over the past 12 months, and down 99.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 7.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 71.4% The company's stock price performance over the past 12 months lags the peer average by 74.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Onconova Therapeutics Inc (ONTX) shares closed today at 0.9% above its 52 week low of $2.28, giving the company a market cap of $49M. The stock is currently down 9.8% year-to-date, down 75.8% over the past 12 months, and down 99.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 44.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 91.8% The company's stock price performance over the past 12 months lags the peer average by 70.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Onconova Therapeutics Inc (ONTX) shares closed today at 1.3% above its 52 week low of $2.34, giving the company a market cap of $50M. The stock is currently down 7.5% year-to-date, down 81.0% over the past 12 months, and down 99.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 9.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 146.2% The company's stock price performance over the past 12 months lags the peer average by 96.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Onconova Therapeutics Inc (ONTX) shares closed today 10.6% higher than it did at the end of yesterday. The stock is currently up 10.6% year-to-date, down 59.6% over the past 12 months, and down 99.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $2.84 and as low as $2.45 this week.Shares closed 90.3% below its 52-week high and 15.1% above its 52-week low.Trading volume this week was 27.7% lower than the 10-day average and 4.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 32.4% The company's stock price performance over the past 12 months lags the peer average by 71.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NEWTOWN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients

NEWTOWN, Pa., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX ), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that early preliminary data from an investigator-initiated Phase 2 open label trial of rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) were presented at the Austrian Society of Dermatology and Venerology Annual Conference 2021, which took place from November 25 27, 2021. RDEB is an ultra-rare condition caused by a lack of type VII collagen protein expression. Type VII collagen protein is responsible for anchoring the skin''s inner layer to its outer layer, and its absence leads to extreme skin fragility and chronic wound formation in RDEB patients. Over time, many of these patients develop squamous cell carcinomas (SCCs) that typically arise in areas of chronic skin wounding and inflammation.